PN6047, which is a novel, selective δ-opioid agonist, is being developed to treat persistent chronic pain. PN6047’s reinforcing potential has been evaluated in conditioned place preference (CPP) using rats as the experimental subjects. Heroin was used as the positive control and hydroxy-propyl-methylcellulose (HPMC) vehicle as the negative control.
